Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Type 2 diabetes (T2D) is a chronic, progressive metabolic disease in which the body becomes resistant to insulin, most often as a result of obesity and sedentary lifestyle. The primary goal of treatment of T2D is to achieve and maintain glycemic control, to reduce the risk of both microvascular complications (, diabetic neuropathy, retinopathy, nephropathy) and macrovascular complications (, myocardial infarction, stroke). Due to the progressive nature of T2D, the number of antidiabetic medications used increases over time. Physicians and treatment guidelines acknowledge the role of metformin as the gold-standard first-line therapy in treating T2D. Further therapies (primarily oral agents such as DPP-IV inhibitors, SGLT-2 inhibitors, and sulfonylureas) are typically added as second- and third-line agents to help maintain long-term glycemic control. A significant number of patients will also require additional treatment with injectable therapies such as the GLP-1 receptor agonists and insulins. Using physician survey data, this report analyzes the use of key therapies in T2D patients. The report provides an analysis of treatment patterns and share by line of therapy between both endocrinologists and primary care physicians (PCPs). The report also investigates the importance of various clinical and performance attributes on choice of therapy, as well as sales representative performance and knowledge of emerging therapies.
Physician research: 45-minute online quantitative survey, fielded between August 26 and September 7, 2015, with several open-ended questions for qualitative feedback completed by 100 U.S. endocrinologists and 90 U.S. PCPs.
Screening criteria: In practice between 2 and 30 years; over 75% of time spent on patient care; endocrinologists have treated at least 100 patients with type 2 diabetes in the past year; PCPs have treated at least 50 patients with type 2 diabetes in the past year.
Deliverables: Report in PowerPoint format; complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request; access to analyst team for presentation or to address questions.
Key Drugs Covered:
- SGLT-2 inhibitors (Invokana, Farxiga, Jardiance)
- GLP-1 analogues (Victoza, Byetta, Bydureon, Tanzeum, Trulicity)
- DPP-IV inhibitors (Januvia, Onglyza, Tradjenta, Nesina)
- Thiazolidinediones (pioglitazone, rosiglitazone)
- Long-acting insulins (Lantus, Levemir, Toujeo)
- Short-acting insulins (Afrezza, Apidra, Humalog, Novolog)
- Other products, including products in late-stage development
Already a Client? Log in to access this report.